Kexing Biopharm's Independently Developed Ophthalmic Innovative Drug GB10 Receives Clinical Trial Approval
Recently, GB10 Injection—a high-concentration ophthalmic-specific protein formulation of an anti-VEGF/Ang-2 dual-target antibody independently developed by the company and holding global intellectual property rights—has officially received the Drug Clinical Trial Approval Notification from the National Medical Products Administration (Acceptance No.: CXSL2500841), granting permission to initiate clinical trials for the treatment of neovascular [...]